Benefício clínico e segurança da imunoterapia combinada e terapia alvo no câncer de próstata
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- International journal of cancer
- Publicado em
- 22 abr 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer
Zeyu Han, Xianyanling Yi, Yaxiong Tang, Xuanji Li, Dazhou Liao, Hang Xu, X Zheng, Jianzhong Ai
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Immunotherapy
- Prostatic Neoplasms
- Molecular Targeted Therapy
- Male
- Combined Modality Therapy
- Humans
- Treatment Outcome
Veja também
Estudos relacionados
- Efficacy and safety of local treatments combined with targeted therapy and immunotherapy versus targeted therapy plus immunotherapy alone in hepatocellular carcinoma: A meta-analysis
- Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis
- Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
- Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis
- Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
- Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis